Tardive
dyskinesia (TD)
is an involuntary neurological movement disorder caused by the use of dopamine
receptor blocking drugs which are prescribed to treat certain psychiatric or
gastrointestinal conditions. Long-term use of these drugs may produce
biochemical abnormalities in the area of the brain known as the striatum.
Access
Detailed Report Summary:
The reasons
that some people who take these drugs may get TD, and some people do not, is
unknown. Tardive dystonia is a more severe form of TD in which slower twisting
movements of the neck and trunk muscles are prominent.
Request
to Get the Sample Pages at:
The typical
symptoms of TD include facial grimacing, sticking out the tongue, and sucking
or fish-like movements of the mouth. INGREZZA (valbenazine), developed by
Neurocrine Biosciences Inc., is one of the key drugs developed for the
treatment of TD.
The drug
candidates in TD pipeline include, but not limited to, SOM3355 and MT-5199.
Some of the companies having drugs in the TD pipeline includes SOM INNOVATION
BIOTECH, SL, and Mitsubishi Tanabe Pharma Corporation.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment